ReviewCureus2025
The Role of Sleep Disturbances in Alzheimer's Disease Progression: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Night-to-night rapid eye movement sleep variability: A relevant marker of early amyloid-β deposition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep disturbances are increasingly recognized as potential contributors to Alzheimer's disease (AD) progression, but their exact role remains debated. This systematic review aims to synthesize existing evidence on the association between sleep disturbances, particularly disruptions in sleep architecture and obstructive sleep apnea (OSA), and cognitive decline or AD biomarkers, while exploring underlying mechanisms. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, 14 studies were selected from a comprehensive search of PubMed, Excerpta Medica Database (Embase), Psychological Information Database (PsycINFO), and Web of Science. Eligible studies included observational and longitudinal designs assessing sleep disturbances and their links to cognitive outcomes or AD pathology. Risk of bias was evaluated using the Newcastle-Ottawa Scale (NOS). Disruptions in rapid eye movement (REM) and non-rapid eye movement (NREM) sleep, such as reduced REM duration and fragmented sleep, were consistently associated with cognitive decline and new-onset dementia. Severe OSA increased AD risk, with hypoxia and sleep fragmentation implicated in neurodegeneration. Both objective (e.g., actigraphy) and subjective sleep measures predicted cognitive impairment, while cerebrospinal fluid (CSF) biomarkers and apolipoprotein E epsilon 4 (APOE ε4) genotype moderated these associations. Mechanistically, sleep disturbances may impair glymphatic clearance and exacerbate amyloid-β accumulation. Sleep disturbances, particularly REM/NREM disruptions and OSA, are robustly linked to AD progression, suggesting their potential as early biomarkers or therapeutic targets. However, causal inferences are limited by observational designs. Future research should prioritize interventional studies to determine whether improving sleep can mitigate AD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.